Accelerated Glofitamab as Urgent Bridging to CAR T-Cell Therapy in High-Risk Relapsed/Refractory Large B-Cell Lymphoma. (PubMed, Hematol Oncol) - Oct 12, 2026 - "Conventional glofitamab step-up dosing reaches the 30-mg target dose approximately 3 weeks after obinutuzumab. Longer-term outcomes could not be attributed to glofitamab alone. These findings are descriptive and require prospective validation."
Journal • Retrospective data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|